

UNIVERSITY HEALTH SERVICES

Dear Part-Time Graduate and Undergraduate Students:

University Health Services (UHS) would like to welcome you to Boston College. The information below details the forms that newly enrolled part-time students must complete. If you are an **international student** here on a **visa**, you must submit additional documents that can be found on our website or the links provided.

Part-time Undergraduate visa-carrying students:

https://www.bc.edu/content/dam/bc1/offices/StudentAffairs/uhs/pdf/Immunization/undergradimmform.pdf

Part-time Graduate visa carrying students:

https://www.bc.edu/content/dam/bc1/offices/StudentAffairs/uhs/pdf/Immunization/gradimmform.pdf

You are required to complete the following:

- TB Questionnaire and Testing Form
 - o To be completed and signed by your provider.
 - Once complete, upload all three pages, the provider-signed form, and any supporting documents to Health Services Portal.
- Meningococcal Disease
 - o Review the Mass Department of Public Health's Informational fact sheet.

Directions to Submit Forms to Health Services Portal:

- Scan or take a picture of <u>each form</u> (immunization, meningitis waiver, and tuberculosis questionnaire/testing form). Save them to your computer or phone. Do not use special characters when naming your files.
- Log in to BC Agora Portal using your BC username and password (https://services.bc.edu)
- Under OTHER SERVICES, click on the HEALTH SERVICES link
- Once in the Health Services Portal, choose the UPLOAD ICON and upload the individual forms to their corresponding line item in the drop-down menu.
- Click SELECT FILE, choose the file you are uploading, and hit the UPLOAD button with each file.
 - o The uploaded documents will appear at the bottom of the page under "Documents Already on File."
- Once forms have been uploaded, go to the top of the page, select the IMMUNIZATION LINK, and enter the dates of all of your vaccines as indicated on your form.
- Once you have entered all vaccine dates, click the SUBMIT button.

Once completed, please **DO NOT** send your original forms to UHS; instead, maintain them for your records if there is a problem with the image quality and you need to resubmit them.

Thank you in advance for your cooperation, and best of luck in your studies.

Yours truly,
Douglas Comeau, DO, CAQSM, FAAFP, FAMSSM
Director, University Health Services and Primary Care Sports Medicine

University Health Services

140 Commonwealth Ave Chestnut Hill, MA 02467 Phone: 617-552- 3225 | Website: <u>bc.edu/UHS</u>

Send us a message: uhs@bc.edu

BC Eagle ID:	
Student Cell Phone:	

Health History Form

		<u> </u>	emographic Inf	•		
		U	emographic ini	ormation		
Last Name			First Name			Middle Initial
Preferred Name		Date of	Birth (MM/DD/YY	YY)		Cell Phone Number
Home Address: Str	eet	City		State	Zip Cod	e Country
Parent/Guardian N	ame	Parent/	Guardian Phone N	lumber		Parent/Guardian Email
Emergency Contac	t Name	Emerge	ncy Contact Phon	e Number		Relationship
			Authorization &	Consent		
(A parer	t/guardian must a	cknowledge and sig	ın this section if the :	student is under th	e age of 18	on the first day of classes)
	ss my care with the c	linic to allow for adeq	uate care delivery and	care management. I		stand that UHS providers within this f specialty care is needed, UHS will provide
Student Name						
Student Signature				Date		
Parent/Guardian S	ignature			Date		
		Hea	alth Insurance I	nformation		
Enter infoUpload a	rmation under N copy of the <i>front</i>	1edical Insurance	nen there is a char in <u>services.bc.edu</u> surance Card to yo hones.	<u> </u>		
		S	Student Medica	l History		
□Ears/Eyes	□Cancer □Heart □Mononucleosis	□Concussion □Kidney/Liver s □Seizures	□Covid-19 □ADD/ADHD □Thyroid	□ Diabetes □ Measles or R □ Other	Rubella	☐ Eating Disorder ☐ Mental Health Condition
Comments.						
Are you currently f	ollowed by a me	dical provider for	a medical condition	on?	□Yes	□ No
Reason:						
Are you currently f	ollowed by a me	dical provider for	any mental health	n conditions?	□Yes	□ No
Reason:	,					
Have you had any	surgical procedu	res?			□Yes	□ No
If yes, list them wit	h the dates:					

University Health Services

140 Commonwealth Ave Chestnut Hill, MA 02467 Phone: 617-552- 3225 | Website: bc.edu/UHS

Send us a message: uhs@bc.edu

BC Eagle ID:	
Student Cell Phone:	

Health History Form				
	Student Me	dical History		
Do you exercise regularly? □Ye	s 🗆 No Any limits:			
Do you smoke or vape? □Ye	s 🗆 No			
Do you consume alcohol? □Ye	s 🗆 No Number of drinks per	week:		
	Alle	rgies		
		on & Food Allergies		
(Include name	and reactions Or If the student ha	as no known allergies please check	the box below)	
□The student has no known alle				
☐The student has no known alle	ergies to food			
Medication(s):				
[//-)				
Food(s):				
Other:				
Do you carry an Epi-Pen? □Yes	□ No			
Do you dairy an Epi Tem. Elles		ledications		
(List all prescription and non-pr		vitamins & herbal supplements, in	cluding dose and times per day)	
Prescription Medication:	Non-prescription medication:	Vitamins:	Herbal supplements:	
·			, ,	
	Family Med	l dical History		
Relation (Parent/Sibling/other	Age:	General Health/Current/Past	If deceased, cause and age of	
family members):		Health Conditions:	death:	
	<u> </u>	I .	<u> </u>	
Please notify the Disability Office if you will need accommodations on campus at 617-552-3470 or				
riease notify the disability office if you will need accommodations of campus at 017-332-3470 of				

student.support@bc.edu.

Please use additional pages if needed for any of the sections.

I certify that the information provided is complete and accurate. I have also received notification of the Health Services privacy policy located on the UHS website: www.bc.edu/uhs.

Student Signature (Required)

Date

University Health Services

140 Commonwealth Ave, Chestnut Hill, MA 02467 Phone: 617-552- 3225 | Website: bc.edu/uhs

Send us a message: uhs@bc.edu

Tuberculosis (Tb) Questionnaire and Testing Form

BC Eagle ID:

BC Email:

Print Last Name:		Print First Name:		Eagle IC)#:	
Date of Birth:	Cell Ph	one #:				
Please refer to this list o	f countries/territories below whe	n responding to questions #4 and #5				
Afghanistan	China, Hong Kong	Haiti	Myanmar		Sout	h Sudan
Algeria	SAR	Honduras	Namibia		Sri La	anka
Angola	China, Macao SAR	India	Nauru		Suda	n
Anguilla	Colombia	Indonesia	Nepal		Surir	iame
Argentina	Comoros	Iraq	Nicaragua		Tajik	istan
Armenia	Congo	Kazakhstan	Niger		Thail	and
Azerbaijan	Democratic People's	Kenya	Nigeria		Timo	r-Leste
Bangladesh	Republic of Korea	Kiribati	Niue		Togo)
Belarus	Democratic Republic	Kuwait	Northern Marian	а	Toke	lau
Belize	of the Congo	Kyrgyzstan	Islands		Tuni	sia
Benin	Djibouti	Lao People's	Pakistan		Turk	menistan
Bhutan	Dominica	Democratic Republic	Palau		Tuva	lu
Bolivia (Plurinational	Dominican Republic	Latvia	Panama		Ugar	nda
State of)	Ecuador	Lesotho	Papua New Guine	ea	Ukra	ine
Bosnia and	El Salvador	Liberia	Paraguay		The	Jnited Republic of
Herzegovina	Equatorial Guinea	Libya	Peru		Tanz	ania
Botswana	Eritrea	Lithuania	Philippines		Urug	uay
Brazil	Eswatini	Madagascar	Qatar		Uzbe	ekistan
Brunei Darussalam	Ethiopia	Malawi	Republic of Korea	1	Vanu	ıatu
Bulgaria	Fiji	Malaysia	Republic of Mold	ova	Vene	ezuela
Burkina Faso	French Polynesia	Maldives	Romania		(Boli	varian
Burundi	Gabon	Mali	Russian Federatio	n	Repu	ıblic of)
Côte d'Ivoire	The Gambia	Malta	Rwanda		Viet	Nam
Cabo Verde	Georgia	Marshall Islands	Sao Tome and		Yem	en
Cambodia	Ghana	Mauritania	Principe		Zam	
Cameroon	Greenland	Mexico	Senegal		Zimb	abwe
Central African	Guam	Micronesia	Sierra Leone			
Republic	Guatemala	(the Federated States of)	Singapore			
Chad	Guinea	Mongolia	Solomon Islands			
China	Guinea-Bissau	Morocco	Somalia			
	Guyana	Mozambique	South Africa			
		bservatory, Tuberculosis Incidence 2020.	Countries with incidence			
<u> </u>	eive a BCG vaccine as a child?	la company and a faction TD disco		☐ Yes	□ No	☐ Unsure
•	•	known or suspected of active TB disea	ase?	☐ Yes☐ Yes	□ No	
	ad a history of a positive PPD s	tories listed above that have a high inc	sidence of active TP	☐ Yes	☐ No	
•	ise CIRCLE the country)	tories listed above that have a high inc	duence of active 1B	163	– 100	
5. Are you a recent	t arrival (<5 years) from one c	of the high prevalence areas listed abo	ove?	☐ Yes	☐ No	
	e the date of arrival: /	more than one month) to one or mor	re of the countries	☐ Yes	☐ No	
•		of TB disease? (If yes, CHECK the coun		la les	– 100	
		r, resident, and/or employee of high-ri		☐ Yes	☐ No	
		k of active TB disease (e.g., correction				
		buse treatment, rehabilitation facility)				
		ollowing groups that may have an incre		☐ Yes	☐ No	
or alcohol?	is infection of active 1B diseas	se – medically underserved, low-incon	ne, or abusing drugs			
ui diculiul!				I	1	

- If the answer to all of the above questions is NO, no further testing is required (no need to complete pages 2 & 3).
- If the answer is <u>YES</u> to any of the above questions, <u>Boston College requires that you receive TB testing</u> as soon as possible but at least before the start of the semester. Or if you have received the BCG Vaccine, you will be required to have a TSPOT, not a PPD test.
 - o Have your physician complete and return the Tuberculosis (TB) Risk Assessment on pages 2 and 3 with additional testing and/or documentation as needed.

University Health Services

140 Commonwealth Ave, Chestnut Hill, MA 02467 Phone: 617-552- 3225 | Website: bc.edu/uhs

Send us a message: uhs@bc.edu

BC Eagle ID:
BC Email:

TUBERCULOSIS	(TB) risk asse	SSMENT
---------------------	-----	-------------	--------

(to be completed by a health care provider)

Clinicians should review and verify information on the **TB Screening Form**. Persons answering **YES** to any of the above questions are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA) *unless a previous positive test is documented*.

History of a positive TB skin test or IGRA blood test? No____Yes____(if Yes, and received previous treatment, complete the TB Symptom Check and the Medication Section)

History of BCG vaccination? (If yes, consider IGRA if possible.) Yes_____No____

Part 1: TB Symptom Check

Does the student have signs or symptoms of active pulmonary tuberculosis disease? Yes_No____

If No, proceed to 2 or 3

If yes, check below:

Cough (especially if lasting for 2-3 weeks or longer) with or without sputum production

Coughing up blood (hemoptysis)

Chest pain

Loss of appetite

Unexplained weight loss, unusual weakness, or extreme fatigue

☐ Night sweats

Fever

Proceed with additional evaluation to exclude active tuberculosis disease, including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

Part 2: Tuberculin Skin Test (TS T)

(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0". The TST interpretation should be based on mm of induration and risk factors.)

Date Given:

Date Read: _____

Result: _mm of induration **Interpretation (please refer to interpretation guidelines): positive __negative (If a positive Chest X-Ray is required, see pg. 3 of 3)

Interpretation Guidelines

>5 mm is positive:

- Recent close contact with an individual with infectious TB
- persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- organ transplant recipients and other immunosuppressed persons (including receiving the equivalent of >15 mg/d of prednisone for 1 month or more)
- HIV-infected persons

>10 mm is positive:

- recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
- injection drug users
- mycobacteriology laboratory personnel
- residents, employees, or volunteers in high-risk congregate settings, for example, prisons, long-term care facilities, health care facilities, homeless shelters, residential facilities for patients with HIV/AIDS
- persons with medical conditions that increase the risk of progression to TB disease, including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer/hematologic disorders (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.
- Children < than 4 years of age or infants, children, and adolescents exposed to adults at high-risk

>15 mm is positive:

• persons with no known risk factors for TB who, except for specific testing programs required by law or regulation, would otherwise not be tested.

* The significance of the travel exposure should be discussed with a healthcare provider and evaluated.

Health Care Provider's Signature:	Date:

University Health Services 140 Commonwealth Ave, Chestnut Hill, MA 02467 Phone: 617-552-3225 | Website: <u>bc.edu/uhs</u> Send us a message: <u>uhs@bc.edu</u>

BC Eagle ID:		
BC Email:		

	Part 3: Interferon Gami	ma Release Assay (IGRA)		
Date Obtained:	Specify Method: 🗆 QI	-T-GIT □ T-Spot	□other	_
Result:negativepositive	indeterminatebord	erline (T-Spot only)		
	Part 4: Chest x-ray: (Require	ed if TST or IGRA is POSITI	IVE)	
Date of chest x-ray:		Result:normal	abnormal	
TUBERCU	LOSIS (TB) RISK ASSESSMEN	T Management of Positive	e TST or IGRA	
All students with a positive TST or IGRA for latent TB with appropriate medication. TB disease and should be prioritized to large la	on. However, students in the begin treatment as soon as exculosis (within the past 2 y uately treated TB disease, in e therapy such as tumor necroms of prednisone per day, of the semellitus, chronic renal faunoileal bypass deal body weight so who abuse drugs and/or along an increased incidence or	e following groups are at possible. ears) ncluding persons with fibrosis factor-alpha (TNF) are immunosuppressive drailure, leukemia, or cance	t increased risk of porotic changes on clantagonists, system rug therapy followier of the head, necl	progression from LTBI to hest radiographs ic corticosteroids ng organ transplantation k, or lung
	MEDICATIO	ON SECTION		
 Was the patient educated and count Does the patient declined treat Does the patient agree to rece Indicate medication(s) prescrib 	\square Yes tment at this time? \square No ive treatment? \square Yes	□ No		f the positive results?
	HFALTH CAF	RE PROVIDER		
	712, (2111 6) (1			
Signature of Provider		Printed Name		Date
Mailing Address		O	office Phone	

Information about Meningococcal Disease, Meningococcal Vaccines, Vaccination Requirements, and the Waiver for Students at Colleges and Residential Schools



Colleges: Massachusetts requires all newly enrolled full-time students 21 years of age and under attending a postsecondary institution (e.g., college) to receive a dose of quadrivalent meningococcal conjugate vaccine on or after their 16th birthday to protect against serotypes A, C, W, and Y **or** fall within one of the exemptions in the law, discussed on the reverse side of this sheet.

Residential Schools: Massachusetts requires all newly enrolled full-time students attending a secondary school who will be living in a dormitory or other congregate housing licensed or approved by the secondary school or institution (e.g., boarding school) to receive the quadrivalent meningococcal conjugate vaccine to protect against serotypes A, C, W, and Y or fall within one of the exemptions in the law, discussed on the reverse side of this sheet.

The law provides an exemption for students signing a waiver that reviews the dangers of meningococcal disease and indicates that the vaccination has been declined. To qualify for this exemption, you are required to review the information below and sign the waiver at the end of this document. Please note that if a student is under 18 years of age, a parent or legal guardian must be given a copy of this document and must sign the waiver.

What is meningococcal disease?

Meningococcal disease is caused by infection with bacteria called *Neisseria meningitidis*. These bacteria can infect the tissue that surrounds the brain and spinal cord called the "meninges" and cause meningitis, or they can infect the blood or other body organs. Symptoms of meningococcal disease may appear suddenly. Fever, severe and constant headache, stiff neck or neck pain, nausea and vomiting, sensitivity to light, and rash can all be signs of meningococcal disease. Changes in behavior such as confusion, sleepiness, and trouble waking up can also be important symptoms. Less common presentations include pneumonia and arthritis. About 350-550 people get meningococcal disease each year in the US, and 10-15% die despite receiving antibiotic treatment. Another 10-20% of those who live lose their arms or legs, become hard of hearing or deaf, have problems with their nervous systems, including long-term neurologic problems, or suffer seizures or strokes.

How is the meningococcal disease spread?

These bacteria are passed from person-to-person through saliva (spit). You must be in close contact with an infected person's saliva in order for the bacteria to spread. Close contact includes activities such as kissing, sharing water bottles, sharing eating/drinking utensils or sharing cigarettes with someone infected, or being within 3-6 feet of someone infected and coughing or sneezing.

Who is at most risk for getting meningococcal disease?

High-risk groups include anyone with a damaged spleen or whose spleen has been removed, those with persistent complement component deficiency (an inherited immune disorder), HIV infection, those traveling to countries where meningococcal disease is prevalent, microbiologists who work with the organism, and people who may have been exposed to the meningococcal disease during an outbreak. People who live in specific settings, such as first-year college students living on campus and military recruits, are also at greater risk of illness from some serogroups.

Which students are most at risk for meningococcal disease?

In the 1990s, first-year college students living in residence halls were identified as being at increased risk for meningococcal disease. Meningococcal disease and outbreaks in young adults were primarily due to serogroup C. However, following many years of routine vaccination of young people with the quadrivalent meningococcal conjugate vaccine (for serogroups A, C, W, and Y), serogroup B is now the primary cause of meningococcal disease and outbreaks in young adults. Among the approximately 9 million students aged 18-21 years enrolled in college, there are an average of 20 cases and 0-4 outbreaks due to serogroup B reported annually. Although incidence of serogroup B meningococcal disease in college students is low, four-year college students are at increased risk compared to non-college students; the risk is highest among first-year students living on campus. The close contact in college residence halls, combined with social mixing activities (such as going to bars, clubs, or parties; participating in Greek life; sharing food or beverages; and other activities involving the exchange of saliva), may put college students at increased risk.

Is there a vaccine against meningococcal disease?

Yes, there are 2 different meningococcal vaccines. Quadrivalent meningococcal conjugate vaccine (Menactra and Menveo) protects against 4 serotypes (A, C, W, and Y) of meningococcal disease. Meningococcal serogroup B vaccine (Bexsero and Trumenba) protects against serogroup B meningococcal disease. Quadrivalent meningococcal conjugate vaccine is routinely recommended at age 11-12 years with a booster at age 16. Students receiving their first dose on or after their 16th birthday do not need a booster. Individuals in certain high-risk groups may need to receive 1 or more of these vaccines based on their doctor's recommendations. Adolescents and young adults (16-23 years of age) who are not in high-risk groups may be vaccinated with the meningococcal B vaccine, preferably at 16-18 years of age, to provide short-term protection for most strains of serogroup B meningococcal disease. Talk with your doctor about which vaccines you should receive.

Is the meningococcal vaccine safe?

Yes. Getting the meningococcal vaccine is much safer than getting the disease. Some people who get the meningococcal vaccine have mild side effects, such as redness or pain where the shot was given. These symptoms usually last for 1-2 days. A small percentage of people who receive the vaccine develop a fever. The vaccine can be given to pregnant women. A vaccine, like any medicine, is capable of causing serious problems such as severe allergic reactions, but these are rare.

MDPH 2020 (see reverse side)

Is meningococcal vaccine mandatory for entry into secondary schools that provide housing and colleges?

Massachusetts law (MGL Ch. 76, s.15D) and regulations (105 CMR 220.000) require both newly enrolled full-time students attending a secondary school (those schools with grades 9-12) who will be living in a dormitory or other congregate housing licensed or approved by the secondary school or institution and newly enrolled full-time students 21 years of age and younger attending a postsecondary institution (e.g., colleges) to receive a dose of quadrivalent meningococcal conjugate vaccine.

The requirements apply to all new full-time residential students at affected secondary schools, regardless of grade (including grades pre-K through 8) and year of study. Secondary school students must provide documentation of having received a dose of quadrivalent meningococcal conjugate vaccine at any time in the past unless they qualify for one of the exemptions allowed by the law. College students 21 years of age and younger must provide documentation of receiving a dose of quadrivalent meningococcal conjugate vaccine on or after their 16th birthday, regardless of housing status, unless they qualify for one of the exemptions allowed by the law. Meningococcal B vaccines are not required and do not fulfill the requirements for receiving the meningococcal vaccine. Whenever possible, immunizations should be obtained before enrollment or registration. However, students may be enrolled or registered if the required immunizations are obtained within 30 days of registration.

<u>Exemptions</u>: Students may begin classes without a certificate of immunization against meningococcal disease if 1) the student has a letter from a physician stating that there is a medical reason why they can't receive the vaccine; 2) the student (or the student's parent or legal guardian, if the student is a minor) presents a statement in writing that such vaccination is against their sincere religious belief; or 3) the student (or the student's parent or legal guardian, if the student is a minor) signs the waiver below stating that the student has received information about the dangers of meningococcal disease, reviewed the information provided and elected to decline the vaccine.

Shouldn't the meningococcal B vaccine be required?

CDC's Advisory Committee on Immunization Practices has reviewed the available data regarding serogroup B meningococcal disease and the vaccines. Currently, there is no standard recommendation and no statewide requirement for meningococcal B vaccination before going to college (although some colleges might decide to have such a requirement). As noted previously, adolescents and young adults (16 through 23 years of age) may be vaccinated with a serogroup B meningococcal vaccine, preferably at 16 through 18 years of age, to provide short-term protection against most strains serogroup B meningococcal disease. This would be a decision between a patient or parent and a healthcare provider. These policies may change as new information becomes available.

Where can a student get vaccinated?

Students and their parents should contact their healthcare provider and make an appointment to discuss the meningococcal disease, the benefits and risks of vaccination, and the availability of these vaccines. Schools and college health services are not required to provide you with this vaccine.

Where can I get more information?

- Your healthcare provider
- The Massachusetts Department of Public Health, Division of Epidemiology and Immunization at (617) 983-6800 or www.mass.gov/dph/imm and www.mass.gov/dph/epi
- Your local health department (listed in the phone book under government)

Waiver for Meningococcal Vaccination Requirement

I have received and reviewed the information provided on the risks of meningococcal disease and the risks and benefits of the quadrivalent meningococcal conjugate vaccine. I understand that Massachusetts' law requires newly enrolled full-time students at secondary schools who are living in a dormitory or congregate living arrangement licensed or approved by the secondary school, and newly enrolled full-time students at colleges and universities who are 21 years of age or younger to receive meningococcal vaccinations unless the students provide a signed waiver of the vaccination or otherwise qualify for one of the exemptions specified in the law.

After reviewing the materials above on the dangers of meningococcal disease, I choose to waive receipt of the meningococcal vaccine.

Student Name:	Date of Birth:	Student ID:
Signature:	Date:	
(Student or parent/legal guardian if th	ie student is under 18 vears of age)	